EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

J Lane, B Langdahl, M Stone, A Kurth, M Oates, J Timoshanko, Z Wang, C Libanati, F Cosman

Osteoporosis International · 2024

DOI: 10.1007/s00198-024-07049-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Osteoporosis International, 2024. Verfasst von J Lane und 8 weiteren Autor:innen. Beteiligte Einrichtung: HSS Ambulatory Care Center, New York, NY, USA. Hauptthemen laut MEDLINE: Osteoporotic Fractures, Bone Density Conservation Agents, Spinal Fractures, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma and Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporotic FracturesBone Density Conservation AgentsSpinal FracturesOsteoporosis, PostmenopausalAntibodies, MonoclonalAlendronateDenosumabHumansFemaleAgedMiddle AgedDouble-Blind MethodBone DensityAged, 80 and overDrug Administration ScheduleRecurrence

Stichwörter der Autor:innen

Bone mineral densityFracture riskOn-study fractureOsteoporosisRomosozumab

Substanzen

romosozumabBone Density Conservation AgentsAntibodies, MonoclonalAlendronateDenosumab

Autor:innen und Institutionen

  • HSS Ambulatory Care Center, New York, NY, USA.
  • Aarhus University Hospital, Aarhus, Denmark.
  • University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, Wales.
  • Department of Orthopaedic and Trauma Surgery Center for Orthopaedic and Trauma Surgery, Marienhaus Klinikum Mainz, Major Teaching Hospital, University Medicine Mainz, Mainz, Germany.
  • Amgen Inc, Thousand Oaks, CA, USA.
  • UCB Pharma, Slough, UK.

Förderung

  • UCB Pharma and Amgen Inc

Zitieren

APA

Lane, J., Langdahl, B., Stone, M., Kurth, A., Oates, M., Timoshanko, J., Wang, Z., Libanati, C., & Cosman, F. (2024). Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporosis International. https://doi.org/10.1007/s00198-024-07049-w

Vancouver

Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J, et al. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporosis International. 2024. doi:10.1007/s00198-024-07049-w

BibTeX
@article{Lane2024,
  author = {Lane, J and Langdahl, B and Stone, M and Kurth, A and Oates, M and Timoshanko, J and Wang, Z and Libanati, C and Cosman, F},
  title = {Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials},
  journal = {Osteoporosis International},
  year = {2024},
  doi = {10.1007/s00198-024-07049-w}
}
Kostenlos starten →